Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Sep 30

PMID 34589419

Citations 3

Authors

Yan Zheng

Yin Li

Xianben Liu

Haibo Sun

Guanghui Liang

Jiajia Hu

Liping Li

Wenqun Xing

Affiliations

Soon will be listed here.

Abstract

Objectives: Lobaplatin (LBP), a third-generation cisplatin derivative has shown promising activity and few side effects in oesophageal squamous cell carcinoma (ESCC) in previous reports. We compared LBP plus docetaxel with cisplatin plus docetaxel as adjuvant chemotherapy in ESCC patients to determine the effects on overall survival (OS) and toxicity.

Methods: A multicentre retrospective study was performed using propensity score matching (PSM) with the Medicine-LinkDoc database. Patients diagnosed with stage II-III ESCC treated with adjuvant chemotherapy (cisplatin plus docetaxel or LBP plus docetaxel) between January 2013 and December 2016 were selected from 6 centres in China.

Results: There were 733 eligible ESCC patients. After PSM (1:1 ratio), 458 patients remained. The 5-year OS rates of the cisplatin and LBP groups were 25.9% and 23.6%, respectively (P=0.457). Leukopenia (grade III-IV/I-II/0: 2.62%/34.5%/59.39% 5.24%/43.23%/45.85%; P=0.0176), neutropenia (grade III-IV/I-II/0: 6.55%/37.56%/51.09% 4.37%/53.28%/36.34%; P=0.0015), nephrotoxicity (grade I-II/0: 13.97%/76.86% 26.64%/65.94%; P<0.001) and gastrointestinal symptoms (grade III-IV/I-II/0: 2.18%/54.59%/32.31% 6.55%/65.07%/20.88%; P=0.0011) were more frequent in the cisplatin group.

Conclusions: Compared with cisplatin plus docetaxel, LBP plus docetaxel provided the same survival benefits but lower side effects of myelosuppression and gastrointestinal symptoms. LBP plus docetaxel might be a choice for adjuvant chemotherapy in ESCC.

Clinical Trial Registration: Lobaplatin or Cisplatin in Adjuvant Chemotherapy for Oesophageal Carcinoma, identifier NCT03413436.

Citing Articles

Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.

Sabatelle R, Colson Y, Sachdeva U, Grinstaff M Mol Pharm. 2024; 21(7):3103-3120.

PMID: 38888089 PMC: 11331583. DOI: 10.1021/acs.molpharmaceut.4c00246.

Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.

Wang C, Yuan L, Wu X, Wang Y, Tian H, Zhang G BMC Med. 2024; 22(1):252.

PMID: 38886794 PMC: 11184884. DOI: 10.1186/s12916-024-03474-0.

Diosmetin suppresses the progression of ESCC by CDK2/Rb/E2F2/RRM2 pathway and synergies with cisplatin.

Chen Y, Dai X, Chen W, Qiao Y, Bai R, Duan X Oncogene. 2023; 42(29):2278-2293.

PMID: 37349644 DOI: 10.1038/s41388-023-02750-2.

References

Gietema J, De Vries E, Sleijfer D, Willemse P, Guchelaar H, Uges D . A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br J Cancer. 1993; 67(2):396-401. PMC: 1968188. DOI: 10.1038/bjc.1993.73. View

Pan S, Sun Y, Sui D, Yang T, Fu S, Wang J . Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018; 102:567-574. DOI: 10.1016/j.biopha.2018.03.109. View

McKeage M . Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2000; 10(1):119-28. DOI: 10.1517/13543784.10.1.119. View

Dilruba S, Kalayda G . Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016; 77(6):1103-24. DOI: 10.1007/s00280-016-2976-z. View

Xie C, Xu Y, Jin W, Lou L . Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anticancer Drugs. 2012; 23(7):698-705. DOI: 10.1097/CAD.0b013e328352cc10. View

Engel J, Martens T, Hahne J, Hausler S, Krockenberger M, Segerer S . Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anticancer Drugs. 2012; 23(4):426-36. DOI: 10.1097/CAD.0b013e32834fb8ce. View

Waissbluth S, Daniel S . Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity. Hear Res. 2013; 299:37-45. DOI: 10.1016/j.heares.2013.02.002. View

Ke L, Xia W, Qiu W, Huang X, Yang J, Yu Y . Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 2017; 17(1):134. PMC: 5311839. DOI: 10.1186/s12885-017-3080-4. View

Sox H, Goodman S . The methods of comparative effectiveness research. Annu Rev Public Health. 2012; 33:425-45. DOI: 10.1146/annurev-publhealth-031811-124610. View

10.

Zhai X, Zheng Q, Yang L, Zhu Y, Li J, Liu Y . Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. Sci Rep. 2017; 7(1):1453. PMC: 5431114. DOI: 10.1038/s41598-017-01347-6. View

11.

Yang J, Wang T, Qiu M, Li Q . Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. Intern Med J. 2015; 45(7):757-61. DOI: 10.1111/imj.12773. View

12.

Chen M, Chen C, Lu H, Xu B . The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. J Thorac Dis. 2015; 7(10):1749-55. PMC: 4635260. DOI: 10.3978/j.issn.2072-1439.2015.10.23. View

13.

Zhang H, Chen R, Wang X, Zhang H, Zhu X, Chen J . Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer. Front Oncol. 2019; 9:538. PMC: 6689983. DOI: 10.3389/fonc.2019.00538. View

14.

Wang N, Lv Y, Xu A, Huang Y, Peng L, Li J . Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma. Asian Pac J Cancer Prev. 2014; 15(2):647-50. DOI: 10.7314/apjcp.2014.15.2.647. View

15.

Wang Z, Xu L, Wang H, Li Z, Lu L, Li X . Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi J Biol Sci. 2018; 25(5):909-916. PMC: 6087814. DOI: 10.1016/j.sjbs.2018.01.011. View

16.

Miyawaki Y, Nakajima Y, Kawada K, Okada T, Tokairin Y, Kawano T . Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Dis Esophagus. 2016; 30(2):1-8. DOI: 10.1111/dote.12485. View

17.

Wu Y, Xu X, Yan F, Sun W, Zhang Y, Liu D . Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer. Onco Targets Ther. 2019; 12:4849-4857. PMC: 6594010. DOI: 10.2147/OTT.S192373. View

18.

Hua S, Kong X, Chen B, Zhuang W, Sun Q, Yang W . Anticancer Mechanism of Lobaplatin as Monotherapy and in Combination with Paclitaxel in Human Gastric Cancer. Curr Mol Pharmacol. 2018; 11(4):316-325. DOI: 10.2174/1874467211666180813095050. View

19.

Liang Y, Wakelee H . Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015; 2(5):403-10. PMC: 4367729. DOI: 10.3978/j.issn.2218-6751.2013.07.01. View

20.

Mao Y, He J, Xue Q, Shao K, Su K, Li N . [Nationwide speaking tour of standardized diagnosis and treatment for esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16(9):801-4. View